Abstract: The present invention is directed to novel antibodies that bind to novel polypeptides encoded by nucleic acids that are differentially expressed in lung, stomach, and melanoma tumors.
Type:
Grant
Filed:
May 2, 2002
Date of Patent:
June 19, 2007
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
Abstract: The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype, based on the relative expression levels of the gene TCCR, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases.
Type:
Application
Filed:
September 29, 2006
Publication date:
June 14, 2007
Applicant:
Genentech, Inc.
Inventors:
Frederic de Sauvage, Iqbal Grewal, Austin Gurney
Abstract: The present invention is directed to methods and means for making and using Angpt13 polypeptides. The invention specifically concerns the use of Angpt13 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angpt13 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.
Type:
Application
Filed:
September 29, 2006
Publication date:
June 14, 2007
Applicant:
GENENTECH, INC.
Inventors:
Napoleone Ferrara, Hans-Peter Gerber, Joe Kowalski, Maria Pisabarro, Daniel Sherman
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 7, 2002
Date of Patent:
June 12, 2007
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 3, 2002
Date of Patent:
June 12, 2007
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
Abstract: The invention is directed to a model system for structure-activity relationship analysis of peptide or protein molecules involved in important biological processes. Provided by the invention are combinatorial peptide libraries comprising peptides with a novel “tryptophan zipper” scaffold (trpzip) that forms stable ?-hairpin structure in solution. Methods of selecting and using such scaffold are provided herein, which are useful for mimicking native protein structures and interactions and designing therapeutic agents. Thus, the invention has profound utility for biological studies and drug development.
Type:
Grant
Filed:
April 12, 2004
Date of Patent:
June 12, 2007
Assignee:
Genentech, Inc.
Inventors:
Andrea G. Cochran, Melissa A. Starovasnik, Nicholas Skelton
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 3, 2002
Date of Patent:
June 12, 2007
Assignee:
Genentech, Inc.
Inventors:
Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Colin K. Watanabe, William I. Wood
Abstract: A gram-negative bacterial cell is described that is deficient in a chromosomal gene present in a wild-type such cell which gene shares at least 80% sequence identity with the native sequence of the yfcK gene and encodes an aminopeptidase. Alternatively, a gram-negative bacterial cell is deficient in a chromosomal gene present in a wild-type such cell which gene encodes an aminopeptidase that shares at least 80% sequence identity with the native sequence of aminopeptidase b2324. Either of these types of cells, when comprising a nucleic acid encoding a heterologous polypeptide, produces an N-terminal unclipped polypeptide when it is cultured and the polypeptide recovered, with virtually no N-terminal clipped polypeptide produced as an impurity. Conversely, a method is provided for cleaving an N-terminal amino acid from a polypeptide comprising contacting the polypeptide with an aminopeptidase sharing at least 80% sequence identity with the native sequence of aminopeptidase b2324.
Abstract: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Application
Filed:
May 22, 2006
Publication date:
June 7, 2007
Applicant:
Genentech, Inc.
Inventors:
Diane Pennica, Victoria Smith, William Wood
Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
Type:
Application
Filed:
September 30, 2006
Publication date:
June 7, 2007
Applicant:
Genentech,Inc.
Inventors:
Terri Davis-Smyth, Helen Chen, Leonard Presta, Napoleone Ferrara
Abstract: The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration of an agent which prevents the interaction of MAdCAM with a MAdCAM binding partner or ligand. These compositions are useful in treating diseases or disorders involving ?4?7/MAdCAM blockade, as well as inhibiting a primary event in the inflammatory response such as blocking interactions between intercellular adhesion molecules and their ligands. Disorders treatable using the methods disclosed herein include infections, especially viral infections, iatrogenic disorders, cholestatic disorders, hereditary disorders, sarcoidosis, organ transplant, and the like. The diagnostic methods of the invention can be employed to detect the presence of a disorder or to monitor the course of therapy used to treat the disorder.
Abstract: The invention provides methods and compositions for improved expression and production of recombinant antibodies in host cell expression systems. In particular, prokaryotic expression and production of antibodies with modified hinge cysteine residues are provided. The invention further provides compositions, kits and articles of manufacture for practicing methods of the present invention.
Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.
Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
September 10, 2002
Date of Patent:
June 5, 2007
Assignee:
Genentech, Inc.
Inventors:
Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
Abstract: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 3, 2002
Date of Patent:
June 5, 2007
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
Abstract: The present invention provides pharmaceutical compositions and methods for liver proliferation and protection. Specifically useful are VEGFR modulating agents capable of promoting liver growth. Disclosed compositions and methods may be useful for promoting proliferation or treating pathological conditions in other organs of significant biological functions.
Type:
Application
Filed:
September 25, 2006
Publication date:
May 31, 2007
Applicant:
Genentech, Inc.
Inventors:
Napoleone Ferrara, Kenneth Hillan, Jennifer Le Couter
Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
Type:
Application
Filed:
September 29, 2006
Publication date:
May 31, 2007
Applicant:
Genentech, Inc.
Inventors:
NAPOLEONE FERRARA, Colin Watanabe, William Wood
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 2, 2002
Date of Patent:
May 29, 2007
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood